Lipplaa A, et al. - In patients with high-risk giant cell tumor of bone (GCTB), researchers assessed 2-year recurrence rate following treatment with adjuvant zoledronic acid vs standard care. Adjuvant zoledronic acid (4 mg) was administered intravenously at 1, 2, 3, 6, 9, and 12 months following surgery in the intervention group participants (n=8), while the control group included 6 patients. In the intervention vs control group, the observed overall 2-year recurrence rate was 38% vs 17%, respectively. Findings revealed that no reduction in the recurrence rate of GCTB was achieved with adjuvant treatment with zoledronic acid. Due to the small sample size, the efficacy could not be determined. All recurrences were seen within the first 15 months after surgery.